{"id":"warfarin-sodium-tablets","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"0.01-0.1","effect":"Warfarin-induced skin necrosis"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-2","effect":"Alopecia"},{"rate":"1-2","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Warfarin is a coumarin anticoagulant that acts as a competitive inhibitor of vitamin K epoxide reductase, preventing the recycling of vitamin K and the gamma-carboxylation of clotting factors II, VII, IX, and X. This results in the production of inactive clotting factors and a prolonged prothrombin time (PT/INR). The anticoagulant effect develops over 36-72 hours as existing clotting factors are cleared from circulation.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:00.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT06655376","phase":"PHASE4","title":"Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-10-02","conditions":"Bleeding, Clot Blood","enrollment":128},{"nctId":"NCT07431762","phase":"PHASE4","title":"Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-02-01","conditions":"Valve Replacement Surgery","enrollment":1058},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT06686628","phase":"PHASE1","title":"An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-20","conditions":"Dermatitis Atopic","enrollment":23},{"nctId":"NCT07362030","phase":"PHASE1","title":"Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-04-14","conditions":"Obesity","enrollment":32},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT05891119","phase":"EARLY_PHASE1","title":"Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-06-03","conditions":"Atopic Dermatitis","enrollment":21},{"nctId":"NCT07128888","phase":"PHASE1","title":"Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-11-17","conditions":"Obesity or Overweight","enrollment":60},{"nctId":"NCT07068841","phase":"PHASE1","title":"Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-05-18","conditions":"Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction","enrollment":24},{"nctId":"NCT06975605","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","status":"COMPLETED","sponsor":"GRIN Therapeutics, Inc.","startDate":"2025-05-20","conditions":"Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders","enrollment":18},{"nctId":"NCT06949124","phase":"PHASE1","title":"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-28","conditions":"Endometriosis, Uterine Fibroids, Assisted Reproduction","enrollment":20},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT06215430","phase":"PHASE1","title":"A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-01-11","conditions":"Healthy","enrollment":16},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT03556592","phase":"PHASE1","title":"Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-08-13","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT06738992","phase":"PHASE4","title":"Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-11-14","conditions":"Mitral Valve Repair Surgery","enrollment":384},{"nctId":"NCT04246762","phase":"PHASE1","title":"Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2021-11-16","conditions":"Rheumatoid Arthritis","enrollment":17},{"nctId":"NCT04254783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-27","conditions":"Ulcerative Colitis (UC), Crohn's Disease","enrollment":20},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT03684564","phase":"PHASE2","title":"RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke","enrollment":43},{"nctId":"NCT05942365","phase":"PHASE1","title":"A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-06-25","conditions":"Drug Drug Interaction, Warfarin, Midazolam","enrollment":28},{"nctId":"NCT06145269","phase":"EARLY_PHASE1","title":"Recanalization Rate of Acute DVT","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"Acute DVT of Lower Extremity","enrollment":100},{"nctId":"NCT04730037","phase":"PHASE3","title":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2021-03-23","conditions":"CTEPH","enrollment":74},{"nctId":"NCT02295475","phase":"PHASE4","title":"Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome","status":"COMPLETED","sponsor":"Scott C. Woller, MD","startDate":"2014-12-10","conditions":"Antiphospholipid Syndrome, Thrombosis","enrollment":48},{"nctId":"NCT04679948","phase":"PHASE1","title":"A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-12-21","conditions":"Healthy","enrollment":16},{"nctId":"NCT05973188","phase":"PHASE4","title":"Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial","status":"UNKNOWN","sponsor":"Peshawar Institute of Cardiology","startDate":"2023-05-01","conditions":"Left Ventricular Thrombus","enrollment":141},{"nctId":"NCT02740712","phase":"PHASE1","title":"Pharmacokinetic Drug-Drug Interaction Study of Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04","conditions":"Neoplasms","enrollment":17},{"nctId":"NCT03911661","phase":"NA","title":"Fearon Algorithm in Warfarin Patient Self-Management","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-11-20","conditions":"Atrial Fibrillation, Venous Thromboses, Heart Valve Diseases","enrollment":30},{"nctId":"NCT02206815","phase":"PHASE4","title":"Safety of \"Ticagrelor+ Warfarin\"in Comparison With \"Clopidogrel+Aspirin+Warfarin\"","status":"COMPLETED","sponsor":"Genshan Ma","startDate":"2014-09-19","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":296},{"nctId":"NCT05273775","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-04-29","conditions":"Chronic Hepatitis B","enrollment":22},{"nctId":"NCT05392127","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-07-15","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168},{"nctId":"NCT03181386","phase":"PHASE3","title":"Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Periodontal Disease, Hemorrhage","enrollment":60},{"nctId":"NCT05300555","phase":"PHASE4","title":"Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":50},{"nctId":"NCT05045313","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-10-20","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT05208398","phase":"PHASE3","title":"Apixaban in Patients With Left Ventricular Thrombus","status":"COMPLETED","sponsor":"Saud Al Babtain Cardiac Center","startDate":"2018-02-18","conditions":"Left Ventricular Thrombus","enrollment":50},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03232398","phase":"PHASE3","title":"Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2018-01-01","conditions":"Acute Myocardial Infarction, Left Ventricular Thrombosis, Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT03926156","phase":"PHASE3","title":"RIvoraxaban in Mitral Stenosis","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2019-05-22","conditions":"Mitral Stenosis, Rheumatic Heart Disease, Atrial Fibrillation","enrollment":40},{"nctId":"NCT04994119","phase":"PHASE1","title":"Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-02-23","conditions":"Pulmonary Arterial Hypertension","enrollment":26},{"nctId":"NCT02982590","phase":"PHASE3","title":"Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2016-11","conditions":"Left Ventricular Thrombosis","enrollment":27},{"nctId":"NCT04709094","phase":"PHASE1","title":"A Drug Interaction Study of Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-28","conditions":"Healthy","enrollment":52},{"nctId":"NCT01569035","phase":"PHASE4","title":"Warfarine in Unexplained Oligohydramnios","status":"TERMINATED","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2009-01","conditions":"Oligohydramnios","enrollment":200},{"nctId":"NCT01769768","phase":"PHASE1","title":"Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Advanced Solid Tumor","enrollment":114},{"nctId":"NCT03799822","phase":"PHASE4","title":"Oral Anticoagulation in Hemodialysis","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2017-05-01","conditions":"Atrial Fibrillation","enrollment":132},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT04235569","phase":"PHASE4","title":"Warfarin Initiation in Mechanical Mitral Valve Replacement Patients","status":"COMPLETED","sponsor":"Sarah Sabry Hashem","startDate":"2018-03-01","conditions":"Mitral Valve Disease","enrollment":50},{"nctId":"NCT02161965","phase":"PHASE4","title":"Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2013-05-21","conditions":"Permanent Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism","enrollment":51},{"nctId":"NCT02247414","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection","status":"COMPLETED","sponsor":"Yangzhou University","startDate":"2014-09","conditions":"Cirrhosis, Hypertension, Status;Splenectomy","enrollment":124},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT00781391","phase":"PHASE3","title":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Stroke, Atrial Fibrillation, Embolism","enrollment":21105},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT00504556","phase":"PHASE2","title":"A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-06","conditions":"Atrial Fibrillation, Thromboembolism","enrollment":1146},{"nctId":"NCT00806624","phase":"PHASE2","title":"DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-10","conditions":"Atrial Fibrillation, Stroke","enrollment":234},{"nctId":"NCT00829933","phase":"PHASE2","title":"Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":536},{"nctId":"NCT01517399","phase":"PHASE1","title":"Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT02610933","phase":"PHASE4","title":"Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2015-11","conditions":"Vascular Calcification","enrollment":117},{"nctId":"NCT02238444","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2014-09-01","conditions":"Cirrhosis, Hypertension, Venous Thrombosis","enrollment":60},{"nctId":"NCT00827034","phase":"PHASE1","title":"A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Alzheimer's Disease, Huntington's Disease","enrollment":14},{"nctId":"NCT00412984","phase":"PHASE3","title":"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12-31","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":20976},{"nctId":"NCT03426033","phase":"PHASE1","title":"Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin","status":"COMPLETED","sponsor":"Akcea Therapeutics","startDate":"2017-12-15","conditions":"Elevated Lipoprotein(a), Cardiovascular Diseases","enrollment":18},{"nctId":"NCT02631057","phase":"","title":"Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-01","conditions":"Atrial Fibrillation","enrollment":4313},{"nctId":"NCT03245307","phase":"PHASE1","title":"A Study To Test The Effect Of Apatinib On P450 Enzymes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-08-22","conditions":"Cytochrome P450 Interaction","enrollment":20},{"nctId":"NCT02157272","phase":"PHASE3","title":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome","status":"TERMINATED","sponsor":"University of Padova","startDate":"2014-12","conditions":"Antiphospholipid Syndrome","enrollment":121},{"nctId":"NCT00401583","phase":"PHASE1","title":"A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07-28","conditions":"Carcinoma, Renal Cell","enrollment":24},{"nctId":"NCT02779348","phase":"PHASE1","title":"Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-09","conditions":"Healthy","enrollment":16},{"nctId":"NCT00404274","phase":"PHASE1","title":"A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-01","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":97},{"nctId":"NCT01996657","phase":"","title":"D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement","status":"COMPLETED","sponsor":"Wuhan Asia Heart Hospital","startDate":"2013-01","conditions":"Heart Valve Disease","enrollment":772},{"nctId":"NCT03183843","phase":"PHASE4","title":"Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses","status":"UNKNOWN","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2016-06-29","conditions":"Mitral Valve Stenosis and Insufficiency, Atrial Fibrillation","enrollment":40},{"nctId":"NCT03058419","phase":"PHASE1","title":"A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-03-14","conditions":"Healthy","enrollment":16},{"nctId":"NCT01400646","phase":"PHASE1","title":"A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":46},{"nctId":"NCT02461914","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-08-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT02017197","phase":"PHASE4","title":"Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-08","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00904176","phase":"PHASE1","title":"Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00700895","phase":"PHASE3","title":"Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2006-08","conditions":"Indications for Warfarin Therapy","enrollment":320},{"nctId":"NCT02617810","phase":"PHASE1","title":"A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT02623296","phase":"PHASE1","title":"A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2015-10","conditions":"Healthy","enrollment":14},{"nctId":"NCT02502110","phase":"PHASE4","title":"Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2015-08","conditions":"Paroxysmal Atrial Fibrillation","enrollment":346},{"nctId":"NCT01006876","phase":"PHASE3","title":"Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2010-01","conditions":"Thromboembolism","enrollment":1584},{"nctId":"NCT00494871","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Atrial Fibrillation","enrollment":1280},{"nctId":"NCT01507051","phase":"PHASE1","title":"Switching Study From Warfarin to Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-11","conditions":"Venous Thrombosis","enrollment":96},{"nctId":"NCT02254148","phase":"PHASE1","title":"The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT02256813","phase":"PHASE1","title":"Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Healthy","enrollment":20},{"nctId":"NCT02243553","phase":"PHASE1","title":"Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01","conditions":"Healthy","enrollment":34},{"nctId":"NCT01111331","phase":"PHASE1","title":"Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Healthy","enrollment":18},{"nctId":"NCT02171494","phase":"PHASE1","title":"Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-09","conditions":"Healthy","enrollment":36},{"nctId":"NCT00329238","phase":"PHASE3","title":"Secondary Prevention of Venous Thrombo Embolism (VTE).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Thromboembolism","enrollment":2867},{"nctId":"NCT00680186","phase":"PHASE3","title":"Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Thromboembolism","enrollment":2589},{"nctId":"NCT01195324","phase":"PHASE1","title":"A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00403767","phase":"PHASE3","title":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-12","conditions":"Atrial Fibrillation, Stroke, Embolism","enrollment":14269},{"nctId":"NCT00643201","phase":"PHASE3","title":"Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Venous Thrombosis","enrollment":5614},{"nctId":"NCT02022527","phase":"PHASE4","title":"Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis","status":"UNKNOWN","sponsor":"Pharmacoeconomic Unit, Egypt","startDate":"2013-06","conditions":"Complications Due to Heart Valve Prosthesis","enrollment":300},{"nctId":"NCT00401414","phase":"NA","title":"Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2007-01","conditions":"Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation","enrollment":344}],"_emaApprovals":[],"_faersSignals":[{"count":112,"reaction":"INTERNATIONAL NORMALISED RATIO DECREASED"},{"count":94,"reaction":"INTERNATIONAL NORMALISED RATIO INCREASED"},{"count":61,"reaction":"PRODUCT QUALITY ISSUE"},{"count":57,"reaction":"INTERNATIONAL NORMALISED RATIO FLUCTUATION"},{"count":40,"reaction":"DRUG INEFFECTIVE"},{"count":31,"reaction":"CONTUSION"},{"count":31,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":26,"reaction":"RASH"},{"count":25,"reaction":"ALOPECIA"},{"count":24,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Casopitant (GW679769) oral tablets"],"phase":"phase_3","status":"active","brandName":"Warfarin Sodium Tablets","genericName":"Warfarin Sodium Tablets","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin Sodium Tablets are used to treat conditions such as Atrial Fibrillation, Thromboembolism, and Aortic Valve Diseases. Warfarin Sodium Tablets are a type of Vitamin K antagonist, which is an intervention studied in clinical trials for anticoagulation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}